Lisata Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025. During the meeting, stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, an amendment to the 2017 Employee Stock Purchase Plan was approved, increasing the number of shares available under the plan from 113,333 to 158,333. Stockholders also decided to hold advisory votes on executive compensation annually. Furthermore, Mohammad Azab, M.D., M.B.A., and Steven Klosk were re-elected as Class III directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.